Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does PIMAVANSERIN Cause Product dose omission issue? 3,808 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 3,808 reports of Product dose omission issue have been filed in association with PIMAVANSERIN (pimavanserin). This represents 8.2% of all adverse event reports for PIMAVANSERIN.

3,808
Reports of Product dose omission issue with PIMAVANSERIN
8.2%
of all PIMAVANSERIN reports
655
Deaths
928
Hospitalizations

How Dangerous Is Product dose omission issue From PIMAVANSERIN?

Of the 3,808 reports, 655 (17.2%) resulted in death, 928 (24.4%) required hospitalization, and 6 (0.2%) were considered life-threatening.

Is Product dose omission issue Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for PIMAVANSERIN. However, 3,808 reports have been filed with the FAERS database.

What Other Side Effects Does PIMAVANSERIN Cause?

Hallucination (10,839) Death (9,352) Drug ineffective (5,545) Confusional state (3,779) Fall (3,366) Delusion (2,421) Hallucination, visual (1,954) Gait disturbance (1,923) Parkinson's disease (1,918) Condition aggravated (1,914)

What Other Drugs Cause Product dose omission issue?

DUPILUMAB (18,189) USTEKINUMAB (9,405) GUSELKUMAB (9,267) LENALIDOMIDE (8,145) MEPOLIZUMAB (5,873) TOFACITINIB (5,646) VOXELOTOR (5,122) BELIMUMAB (4,671) SECUKINUMAB (4,572) APREMILAST (4,460)

Which PIMAVANSERIN Alternatives Have Lower Product dose omission issue Risk?

PIMAVANSERIN vs PIMECROLIMUS PIMAVANSERIN vs PIMOZIDE PIMAVANSERIN vs PINAVERIUM PIMAVANSERIN vs PINDOLOL PIMAVANSERIN vs PIOGLITAZONE

Related Pages

PIMAVANSERIN Full Profile All Product dose omission issue Reports All Drugs Causing Product dose omission issue PIMAVANSERIN Demographics